Lead Sponsor

Pliant Therapeutics, Inc.

Collaborators

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of IPF, within 5 years prior to Screening,
•FVC %predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screening.
•DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted if within 1 month of screening.
•Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if on a stable dose for at least 3 months

•Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA
•Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio \<0.7
•Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression
•Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening
•Smoking of any kind within 3 months of Screening

Related studies

NCT05842681 · Idiopathic Pulmonary Fibrosis

NCT06951217 · Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

NCT07194382 · Idiopathic Pulmonary Fibrosis (IPF)

NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

NCT07299695 · Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/